GSK exits Ideaya partnership

GSK has quietly terminated its synthetic lethality collaboration with Ideaya Biosciences, returning the last two assets in the partnership, according to an SEC filing. GSK's decision to walk away from IDE275, a Werner helicase inhibitor, and IDE705, a DNA Pol theta (polymerase θ) inhibitor, follows the UK company's earlier return of the MAT2A inhibitor IDE397, which Ideaya has continued to advance on its own, and which has since delivered some early clinical responses. What Ideaya plans to do with IDE275 and IDE705 is unclear; the company says it will assess “strategic options” in 2026, but the future for both modalities remains uncertain. The Werner inhibitor field has faced scepticism after Roche handed RO7589831 back to Vividion, and Novartis presented underwhelming data with HRO761 at this year’s ESMO. Meanwhile the Pol theta inhibitor landscape has also been challenged. Artios is the only company to have reported clinical results to date, but activity with its contender ART6043 appeared only when combined with Lynparza. Ideaya has various other programmes in development, the most advanced being the PKC inhibitor daravosertib. GSK, meanwhile, struck another early deal this week, with Oxford Biotherapeutics, although no details were given about projects, targets, or financial terms.

Ideaya's pipeline 

Source: OncologyPipeline.